Showing results (111-120 of 174) with videos related to

Sort By:
Pageof 18
Cancers|April 27, 2024
Drug Cost Avoidance Resulting from Participation in Clinical Trials: A 10-Year Retrospective Analysis of Cancer Patients with Solid TumorsMaria-Josep Carreras, Berta Renedo-Miró, Carolina Valdivia, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2026
Quality and safety of research biopsies in oncology clinical trialsPaolo Nuciforo, Fiorella Ruiz-Pace, José Jimenez, et al.
Frontiers in Digital Health|December 15, 2025
UpSMART: five years of digital innovation in cancer clinical research-achievements, challenges, and recommendationsPaul O'Regan, Fouziah Butt, Louise Carter, et al.
Cancer|July 23, 2026
Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansionEugene Shenderov, Manish R Sharma, Elena Garralda, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsRavit Geva, Maria Vieito, Jorge Ramon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2025
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical TrialsJia Liu, Max Farrow, Lesley Seymour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2025
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid TumorsAnthony El-Khoueiry, Omar Saavedra, Jacob Thomas, et al.
Nature Communications|January 6, 2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trialMrinal Gounder, Melissa Johnson, Rebecca S Heist, et al.
Lancet (London, England)|July 26, 2011
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studySebahattin Cirak, Virginia Arechavala-Gomeza, Michela Guglieri, et al.
Cancer Research Communications|December 21, 2023
Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 ExpressionMarta Ligero, Garazi Serna, Omar S M El Nahhas, et al.
Pageof 18